ABSTRACT Objective. The aim of the current study was to investigate the relationship between self-reported severity of cannabis dependence and symptoms of depression. Method. The lifetime diagnoses of depression and cannabis misuse (abuse and/or dependence) were obtained from 50 participants recruited from the general community, using a self-completed diagnostic interview (CIDI-Auto 2.1). The lifetime severity of cannabis dependence was established using a standard questionnaire, Severity of Dependence Scale (SDS). Results. Of the 19 participants with mental illness diagnoses, 14 (74%) reported depression symptoms. The 14 participants with depression diagnoses had significantly more cannabis misuse diagnoses and significantly higher SDS scores compared to those without mental illness diagnoses (N = 31). SDS scores significantly predicted presence or absence of CIDI depression diagnoses with a 69% overall rate of cor-rect predictions. As SDS scores increased the odds of classification into depressed versus non-depressed groups was 1.3 (95% C.I. 1.02-1.57). Conclusion. The presence of lifetime depression symptoms is associated with higher lifetime severity of cannabis dependence and more lifetime cannabis misuse symptoms in otherwise healthy research vol-unteers.
Cite this paper
nullKedzior, K. & Martin-Iverson, M. (2010). Association between Severity of Cannabis Dependence and Depression. Psychology, 1, 233-237. doi: 10.4236/psych.2010.14031.
 H. Verdoux, “Cannabis and psychosis proneness,” In D. Castle and R. Murray, Eds., Marijuana and Madness: Psychiatry and Neurobiology, Cambridge University Press, New York, 2004, pp. 75-88.
 L. Degenhardt, W. Hall, M. Lynskey, C. Coffey and G. Patton, “The Association between Cannabis Use and Depression: A Review of the Evidence,” In: D. Castle and R. Murray, Eds., Marijuana and Madness: Psychiatry and Neurobiology, Cambridge University Press, New York, 2004, pp. 54-74.
 American Psychiatric Association, “Diagnostic and Statistical Manual of Mental Disorders (DSM-IV),” American Psychiatric Association, 1994.
 K. Kedzior and M. Martin-Iverson, “Chronic Cannabis Use is Associated with Attention-Modulated Reduction in Prepulse Inhibition of the Startle Reflex in Healthy Humans,” Journal of Psychopharmacology, Vol. 20, No. 4, 2006, pp. 471-484.
 World Health Organi-zation, “Composite International Diagnostic Interview (CIDI), Version 2.1,” World Health Organisation, 1997.
 M. Gos-sop, S. Darke, P. Griffiths, J. Hando, B. Powis, W. Hall and J. Strang, “The Severity of Dependence Scale (SDS): Psychometric Properties of the SDS in English and Australian Samples of Heroin, Cocaine and Amphetamine Users,” Addiction, Vol. 90, 1995, pp. 607-614.
 K. Kedzior, J. Badcock and M. Mar-tin-Iverson, “Validity and Consistency of Self-Reports Regard-ing Substance Use in General Research Volunteers, Including Regular Cannabis Users and Schizophrenia Patients,” Substance Use and Misuse, Vol. 41, No. 5, 2006, pp. 743-750.
 C. Ferri, J. Marsden, M. de Araujo, R. Laranjeira and M. Gossop, “Validity and Reliability of the Severity of Dependence Scale (SDS) in a Brazilian Sample of Drug Users,” Drug & Alcohol Review, Vol. 19, No. 4, 2000, pp. 451-455.
 M. Gossop, D. Best, J. Marsden and J. Strang, “Test-Retest Reliability of the Severity of Dependence Scale (Comment),” Addiction, Vol. 92, No. 3, 1997, pp. 353.
 G. Martin, J. Copeland, P. Gates and S. Gilmour, “The Severity of Dependence Scale (SDS) in an Adolescent Population of Cannabis Users: Reliability, Validity and Diagnostic Cut-Off,” Drug and Alcohol Dependence, Vol. 83, No. 1, 2006, pp. 90-93.
 H.-U. Wittchen, “Reliability and Validity Studies of the WHO—Composite International Diagnostic Interview (CIDI): A Critical Review,” Journal of Psychiatric Research, Vol. 28, No. 1, 1994, pp. 57-84.
 G. Andrews and L. Peters, “The Psychometric Properties of the Composite International Diagnostic Interview,” Social Psychiatry & Psychiatric Epidemiology, Vol. 33, No. 2, 1998, pp. 80-88.
 K. Kedzior and M. Martin-Iverson, “Concurrent Validity of Cannabis Misuse Diagnoses on CIDI-Auto 2.1 in Low-Level Cannabis Users from the General Population,” Australian Journal of Psychology, Vol. 59, No. 3, 2007, pp. 169-175.
 S. Bagley, H. White and B. Golomb, “Logistic Regression in the Medical Literature: Standards for Use and Reporting, with Particular Attention to One Medical Domain,” Journal of Clinical Epidemiology, Vol. 54, No. 10, 2001, pp. 979-985.
 R. Pertwee and R. Ross, “Cannabinoid Receptors and their Ligands,” Prostaglandins Leukotrienes & Essential Fatty Acids, Vol. 66, No. 2-3, 2002, pp. 101-121.
 T. Moore, S. Zammit, A. Lingford-Hughes, T. Barnes, P. Jones, M. Burke and G. Lewis, “Cannabis Use and Risk of Psychotic or Affective Mental Health Outcomes: A Systematic Review,” Lancet, Vol. 370, No. 9584, 2007, pp. 319-328.